Reduction in sweat testing of carriers can be achieved if only infants with two CF-causing, pathogenic, or likely pathogenic CFTR variants are considered screen-positive and referred for follow-up (Figure 2; see also Considerations for Implementation). Here, CFTR is linked to cystic fibrosis.